Does Faecalibacterium prausnitzii produce butyrate and anti-inflammatory metabolites that support gut barrier resilience and calm mucosal immunity?

Faecalibacterium prausnitzii, a dominant commensal bacterium in the human colon, plays a vital role in maintaining intestinal homeostasis through targeted metabolic and immunological activities.

Biochemical production and key metabolites

• Metabolic synthesis: F. prausnitzii produces butyrate via the acetyl-CoA pathway, relying entirely on the butyryl-CoA:acetate CoA-transferase (BUT) enzyme, which utilizes extracellular acetate from neighboring gut taxa.
• Secreted protein effectors: Beyond butyrate, the bacterium secretes the ~15 kDa Microbial Anti-inflammatory Molecule (MAM) protein and small molecules like isopentenyladenine.

Epithelial barrier reinforcement

• Tight junction assembly: Butyrate and MAM increase transepithelial electrical resistance (TEER) and reduce paracellular permeability.
• Intracellular signaling: Butyrate activates AMP-activated protein kinase (AMPK), accelerating the relocation of zonula occludens-1 (ZO-1) and occludin. Concurrently, butyrate acts as a histone deacetylase (HDAC) inhibitor targeting HDAC 1, 3, and 8.

Mucosal immune regulation

• NF-κB suppression: Butyrate binds to G-protein coupled receptors (specifically GPR109A, GPR43, and GPR41) to suppress NF-κB. MAM complements this by stabilizing the IKK complex to block NF-κB activation, downregulating inflammatory chemokines like IL-8.
• Tolerogenic rewiring: These metabolites promote the differentiation of IL-10-producing regulatory T cells (specifically CD4⁺CD8α⁺ or DP8α Tregs) while suppressing the Th1/Th17 axis and reducing pro-inflammatory cytokines (IL-12, TNF-α, and IFN-γ).

Bottom line

• F. prausnitzii utilizes a highly coordinated dual-pillar system of butyrate and the MAM protein to systematically strengthen the epithelial barrier and calm mucosal immune activity, establishing its critical role in gut health.